News
11-09-2015, 08:50 PM
Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, confirmed today the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene’s Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer.
More... (http://www.news-medical.net/news/20151109/Oasmia-Pharmaceuticale28099s-Paclical-is-bioequivalent-of-Celgenee28099s-Abraxane-in-treatment-of-women-with-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20151109/Oasmia-Pharmaceuticale28099s-Paclical-is-bioequivalent-of-Celgenee28099s-Abraxane-in-treatment-of-women-with-metastatic-breast-cancer.aspx)